Below: the three compounds, the stacks researchers run alongside, and a decision tree if you're not sure where to start
Switching from Semaglutide, a GLP-1 receptor agonist, to Zepbound (Tirzepatide) is possible, but should be done under the supervision of your healthcare provider
Rybelsus Semaglutide Tablets 14mg Request Callback 9000 / Strip Get Latest Price Product Brochure Rybelsus 14 mg is a once-daily, oral GLP-1 receptor agonist containing semaglutide used to improve glycemic control in adults with Type 2 diabetes
Successful examples include semaglutide (168h), an oral octreotide formulation (restricted maintenance indication), and emerging candidates such as I-338 insulin (60h), which used sodium caprate (C10) in Novo Nordisks Phase II, trials ( 7.1 Application to FDA-approved and emerging peptides Table 2 applies this framework to representative FDA-approved peptides and emerging candidates, demonstrating how few molecules meet the criteria for oral feasibility and why the historical record of failure is the expected outcome rather than a surprising result
Strategy 3: Use the accelerated titration approach
A1C & T2D Control: Tirzepatide -2.3% vs -1.8% For type 2 diabetes management, tirzepatide met superiority over semaglutide across all doses in the SURPASS-2 trial